Publications by authors named "Jorge Blanco-Anesto"
Menopause is a complex period in women's life, when weight gain and predisposition to obesity are frequent. Moreover, even during menopause transition, women begin to lose lean mass up to 0.5% and, therefore, an increase in the percentage of fat mass with central distribution and an increased risk of metabolic syndrome.
View Article and Find Full Text PDFArticle Synopsis
- Obesity is becoming increasingly widespread, and while liraglutide 3 mg was effective in helping some people lose weight, many did not achieve their goals, highlighting the need for more treatment options.
- Recent STEP trials revealed that semaglutide is more effective than liraglutide for weight loss, leading to a study comparing the effects of weekly semaglutide 0.5 mg to daily liraglutide 3 mg in real-life scenarios for three months.
- Among 179 participants, those on semaglutide experienced a significant weight reduction, indicating that it may be a viable alternative to liraglutide despite differences in initial body compositions.
Introduction: grade 3 and 4 obesity is a chronic and progressive disease. Liraglutide 3 mg could be an effective adjuvant therapy in these subjects. Objectives: to evaluate changes in weight loss, body composition, metabolic parameters and vitamin D levels in subjects with grade 3 and 4 obesity treated for 8 months with liraglutide 3 mg.
View Article and Find Full Text PDFAims: to assess the prevalence of metabolic health in Mallorca obese patients. Methods: participants were classified in metabolically healthy obese (MHO) and metabolically non-healthy obese (MNHO). Food, toxic and lifestyle habits, time of obesity evolution, breastfeeding, obesity in childhood and family history of obesity and diabetes mellitus, as well as glycemia, total cholesterol, HDL-cholesterol and triglyceridemia were evaluated in 457 obese patients.
View Article and Find Full Text PDF